Literature DB >> 9336131

Is the time interval between surgery and radiotherapy important in operable nonsmall cell lung cancer? A retrospective analysis of 340 cases.

F Würschmidt1, H Bünemann, M Ehnert, H P Heilmann.   

Abstract

PURPOSE: To evaluate the influence of prognostic factors in postoperative radiotherapy of NSCLC with special emphasis on the time interval between surgery and start of radiotherapy. METHODS AND MATERIALS: Between January 1976 and December 1993, 340 cases were treated and retrospectively analyzed meeting the following criteria: complete follow-up; complete staging information including pathological confirmation of resection status; maximum interval between surgery (SX) and radiotherapy (RT) of 12 weeks (median 36 days, range 18 to 84 days); minimum dose of 50 Gy (R0), and maximum dose of 70 Gy (R2). Two hundred thirty patients (68%) had N2 disease; 228 patients were completely resected (R0). One hundred six (31%) had adenocarcinoma, 172 (51%) squamous cell carcinoma.
RESULTS: In univariate analysis, Karnofsky performance status (90+ >60-80%; p = 0.019 log rank), resection status stratified for nodal disease (R+ <R0; p = 0.046), and the time interval between SX and RT were of significant importance. Patients with a long interval (37 to 84 days) had higher 5-year survival rates (26%) and a median survival time (MST: 21.9 months, 95% C.I. 17.2 to 28.6 months) than patients with a short interval (18 to 36 days: 15%; 14.9 months, 13 to 19.9 months; p = 0.013). A further subgroup analysis revealed significant higher survival rates in patients with a long interval in N0/1 disease (p = 0.011) and incompletely resected NSCLC (p = 0.012). In multivariate analysis, the time interval had a p-value of 0.009 (nodal disease: p = 0.0083; KPI: p = 0.0037; sex: p = 0.035).
CONCLUSION: Shortening the time interval between surgery and postoperative radiotherapy to less than 6 weeks even in R+ cases is not necessary. Survival of patients with a long interval between surgery and start of radiotherapy was better in this retrospective analysis as compared to patients with a short interval.

Entities:  

Mesh:

Year:  1997        PMID: 9336131     DOI: 10.1016/s0360-3016(97)00380-5

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

1.  Potential clinical predictors of outcome after postoperative radiotherapy of non-small cell lung cancer.

Authors:  R Bütof; K Kirchner; S Appold; S Löck; A Rolle; G Höffken; M Krause; M Baumann
Journal:  Strahlenther Onkol       Date:  2014-01-12       Impact factor: 3.621

2.  Optimal sequencing of postoperative radiotherapy and chemotherapy in IIIA-N2 non-small cell lung cancer.

Authors:  Ugur Selek; Joe Y Chang
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

3.  Making molehills out of a mountain: experience with a new scheduling strategy to diminish workload variations in response to increased treatment demands.

Authors:  A Waters; M Alizadeh; C Filion; F Ashbury; J Pun; M P Chagnon; A Legrain; M A Fortin
Journal:  Curr Oncol       Date:  2016-08-12       Impact factor: 3.677

Review 4.  [Delays and treatment interruptions: difficulties in administering radiotherapy in an ideal time-period].

Authors:  Carmen González San Segundo; Felipe A Calvo Manuel; Juan Antonio Santos Miranda
Journal:  Clin Transl Oncol       Date:  2005-03       Impact factor: 3.405

5.  PORTAF - postoperative radiotherapy of non-small cell lung cancer: accelerated versus conventional fractionation - study protocol for a randomized controlled trial.

Authors:  R Bütof; M Simon; S Löck; E G C Troost; S Appold; M Krause; M Baumann
Journal:  Trials       Date:  2017-12-20       Impact factor: 2.279

6.  How Long Are Cancer Patients Waiting for Oncological Therapy in Poland?

Authors:  Karolina Osowiecka; Monika Rucinska; Jacek J Nowakowski; Sergiusz Nawrocki
Journal:  Int J Environ Res Public Health       Date:  2018-03-23       Impact factor: 3.390

7.  Survival Impact of Delaying Postoperative Radiotherapy in Patients with Esophageal Cancer.

Authors:  Yuanyuan Wang; Shanghui Guan; Yanhong Bi; Sixiang Lin; Jianjun Ma; Qian Xing; Chonghua Liu; Rui Zhang; Zhen Qu; Peng Jiang; Xue Chen; Yufeng Cheng
Journal:  Transl Oncol       Date:  2018-09-06       Impact factor: 4.243

8.  Impact of delays in radiotherapy of head and neck cancer on outcome.

Authors:  Barbara Žumer; Maja Pohar Perme; Simona Jereb; Primož Strojan
Journal:  Radiat Oncol       Date:  2020-08-20       Impact factor: 3.481

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.